Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 0.48 |
| ▸ | USP7 | Q93009 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 4/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1322888 | 0.83 | SLC6A4 (0.61) | SLC6A4GBA1SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL4772849 | 0.82 | SLC6A4 (0.60) | SLC6A4GBA1SLC6A2SLC6A3 | |
| SCHEMBL28086989 | 0.81 | FPR2 (0.48) | SLC6A4GBA1SLC6A2SLC6A3 | |
| SCHEMBL26144454 | 0.81 | SLC6A4 (0.48) | SLC6A4GBA1DPP4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL7400237 | 0.79 | SLC6A4 (0.47) | SLC6A4GBA1SLC6A2SLC6A3 | |
| SCHEMBL25145955 | 0.78 | SLC6A4 (0.56) | SLC6A4GBA1SLC6A2SLC6A3 | |
| SCHEMBL25145660 | 0.78 | SLC6A4 (0.49) | SLC6A4GBA1SLC6A2SLC6A3 | |
| SCHEMBL5207446 | 0.77 | SLC6A4 (0.48) | SLC6A4GBA1 | |
| SCHEMBL5205023 | 0.77 | PRMT5 (0.46) | SLC6A4GBA1SLC6A2SLC6A3 | |
| SCHEMBL20524638 | 0.77 | TDP1 (0.50) | SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330460-B1 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2007-03-21 | — | — | EP | disclosed |
| US-6939871-B2 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-09-06 | — | — | US | disclosed |
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C (GB) | 2004-04-01 | — | — | US | disclosed |
| CN-1478092-A | Benzoxazinone derivatives, their preparation and use | ʷ | 2004-02-25 | — | — | CN | disclosed |
| EP-1330460-A2 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002034754-A2 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | CYP2B6, CBR1, CYP2A6 | SLC6A4 1029/4885USP7 3731/4885GBA1 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.